Alebund Pharmaceuticals (Jiangsu) Limited Class H

Alebund Pharmaceuticals (Jiangsu) Limited Class H

HHKEX:9637
19.95
HKD
-0.15
(-0.75%)
15.61BMarket Cap
Mar 03Next Earn
Alebund Pharmaceuticals (Jiangsu) Limited Class H
HKEX:9637
(Hong Kong Exchange)

Recent

price

19.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2024
2025
CNY
0.02
0.09
Revenue per Share
-0.96
-2.21
Basic EPS, GAAP
-1.43
-1.15
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
-3.91
1.48
Book Value per Share
-3.95
1.45
Tangible Book Value per Share
340
340
Basic Weighted Avg Shares
7
31
Sales/Revenue/Turnover
-4,703.48
-2,098.64
Operating Margin (%)
13
45
Depreciation Expense
-326
-750
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
-4,996.57
-2,454.63
Profit Margin (%)
-1,555
319
Working Capital
447
546
LT Debt
-1,341
503
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

CNY

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-137.52%
Free Cash Flow
- -
- -
-19.95%
Net Income, GAAP
- -
- -
130.05%
Sales/Revenue/Turnover
- -
- -
368.29%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
7
2025
- -
- -
31
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.96
2025
- -
- -
-2.21
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Alebund Pharmaceuticals (Jiangsu) Limited is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel therapeutics for chronic kidney disease and related metabolic and renal disorders. The company operates an integrated nephrology-focused therapeutic pipeline comprising small molecule therapies and biologics; AP301, an oral, next-generation fiber-iron-based phosphate binder indicated for the treatment of hyperphosphatemia in chronic kidney disease patients undergoing maintenance dialysis; AP306 (EOS789), an oral first-in-class pan-inhibitor of sodium-dependent phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) developed for hyperphosphatemia management; AP303, an oral small-molecule dual peroxisome proliferator-activated receptor agonist developed for diabetic kidney disease, focal segmental glomerulosclerosis, and autosomal dominant polycystic kidney disease; AP308, an engineered recombinant immunoglobulin A protease engineered for the treatment of immunoglobulin A nephropathy; MIRCERA (AP601), a long-acting continuous erythropoietin receptor activator commercialized for the treatment of symptomatic anemia associated with chronic kidney disease; and early-stage pipeline assets including AP304, AP305, and AP307 for diverse kidney disease subtypes; alongside in-house pharmaceutical development, pilot-scale drug formulation, and commercial-scale manufacturing services. Founded in 2018, the company is headquartered in Yangzhou, Jiangsu Province, China, with clinical development and executive operations in Shanghai, China, and conducts multinational research and clinical trial programs across Greater China, North America, and other international markets. In recent corporate and clinical developments, the company completed its initial public offering on the Main Board of the Stock Exchange of Hong Kong under the stock code 9637 in June 2026, raising approximately HKD 1.28 billion, and was subsequently admitted to eligible securities for Southbound Trading under the Stock Connect scheme in September 2026. In August 2026, China's National Medical Products Administration accepted for review the New Drug Application for AP301 following the completion of registrational trials in China and alongside the global Phase III RESPOND-2 trial. In July 2026, the company randomized and dosed the first subject in a global Phase IIb multi-regional clinical trial for AP306, a candidate holding Breakthrough Therapy Designation from China's National Medical Products Administration that is co-developed globally with R1 Therapeutics pursuant to an exclusive worldwide out-licensing and equity partnership executed in March 2026. Additionally, in September 2026, the company received Investigational New Drug clearance from the United States Food and Drug Administration to advance AP308 into clinical trials, while fully commissioning its centralized drug manufacturing facility in Yangzhou following receipt of a Category B Drug Manufacturing License from the Jiangsu Provincial Drug Administration.